BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1386 related articles for article (PubMed ID: 27030274)

  • 21. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire.
    Ondoa P; Koblavi-Dème S; Borget MY; Nolan ML; Nkengasong JN; Kestens L
    Clin Exp Immunol; 2005 Apr; 140(1):138-48. PubMed ID: 15762885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus.
    Petrara MR; Cattelan AM; Sasset L; Freguja R; Carmona F; Sanavia S; Zanchetta M; Del Bianco P; De Rossi A
    PLoS One; 2017; 12(9):e0185128. PubMed ID: 28926641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood.
    Bitnun A; Samson L; Chun TW; Kakkar F; Brophy J; Murray D; Justement S; Soudeyns H; Ostrowski M; Mujib S; Harrigan PR; Kim J; Sandstrom P; Read SE
    Clin Infect Dis; 2014 Oct; 59(7):1012-9. PubMed ID: 24917662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.
    Taiwo B; Hunt PW; Gandhi RT; Ellingson A; McKenna M; Jacobson JM; Gripshover B; Bosch RJ
    J Acquir Immune Defic Syndr; 2013 May; 63(1):101-4. PubMed ID: 23392463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.
    Avettand-Fènoël V; Hocqueloux L; Ghosn J; Cheret A; Frange P; Melard A; Viard JP; Rouzioux C
    Clin Microbiol Rev; 2016 Oct; 29(4):859-80. PubMed ID: 27559075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
    Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
    Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
    Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
    Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M
    AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-molecule techniques to quantify and genetically characterise persistent HIV.
    Wang XQ; Palmer S
    Retrovirology; 2018 Jan; 15(1):3. PubMed ID: 29316955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy.
    Koblavi-Dème S; Maran M; Kabran N; Borget MY; Kalou M; Kestens L; Maurice C; Sassan-Morokro M; Ekpini ER; Roels TH; Chorba T; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S17-22. PubMed ID: 14565605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy.
    Wasmuth JC; Hackbarth F; Rockstroh JK; Sauerbruch T; Spengler U
    HIV Med; 2003 Apr; 4(2):111-9. PubMed ID: 12702131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4
    Jones BR; Miller RL; Kinloch NN; Tsai O; Rigsby H; Sudderuddin H; Shahid A; Ganase B; Brumme CJ; Harris M; Poon AFY; Brockman MA; Fromentin R; Chomont N; Joy JB; Brumme ZL
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31776273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
    Almeida M; Cordero M; Almeida J; Orfao A
    Cytometry B Clin Cytom; 2007 Jan; 72(1):22-33. PubMed ID: 17051525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.
    Ruggiero A; De Spiegelaere W; Cozzi-Lepri A; Kiselinova M; Pollakis G; Beloukas A; Vandekerckhove L; Strain M; Richman D; Phillips A; Geretti AM;
    EBioMedicine; 2015 Sep; 2(9):1153-9. PubMed ID: 26498496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.
    Khoury G; Fromentin R; Solomon A; Hartogensis W; Killian M; Hoh R; Somsouk M; Hunt PW; Girling V; Sinclair E; Bacchetti P; Anderson JL; Hecht FM; Deeks SG; Cameron PU; Chomont N; Lewin SR
    J Infect Dis; 2017 Mar; 215(6):911-919. PubMed ID: 28453847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells.
    Gray CM; Lawrence J; Ranheim EA; Vierra M; Zupancic M; Winters M; Altman J; Montoya J; Zolopa A; Schapiro J; Haase AT; Merigan TC
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1357-69. PubMed ID: 11018855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
    Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
    J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
    Beran O; Holub M; Spála J; Kalanin J; Stanková M
    Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.